论文部分内容阅读
[目的]观察丹参酚酸B盐(SA-B)对肝硬化门静脉高压的疗效。[方法]以0.5%二甲基亚硝胺(DMN)腹腔注射建立大鼠肝硬化动物模型,模型成功后开始给予SA-B治疗,测定各组大鼠血清中丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、清蛋白(Alb)、总胆红素(Tbil)以及肝组织中羟脯氨酸(Hyp)和内皮素-1(ET-1)的水平,肠系膜上静脉插管测定门静脉压力,观察肝组织病理形态的变化,并与模型组比较。[结果]治疗组门静脉压力明显降低,血清ALT、AST、Tbil及肝组织Hyp和ET-1水平与模型组比较均显著下降,病理学显示治疗组基本恢复正常。[结论]肝硬化时肝组织中ET-1显著升高;SA-B能显著降低肝硬化时升高的门静脉压力和肝组织中ET-1的水平。
[Objective] To observe the curative effect of salvianolic acid B salt (SA-B) on cirrhotic portal hypertension. [Method] The animal model of hepatic cirrhosis was established by intraperitoneal injection of 0.5% dimethylnitrosamine (DMN). SA-B treatment was started after the model was successfully established. Serum alanine aminotransferase (ALT) Aspartate aminotransferase (AST), albumin (Alb), total bilirubin (Tbil) and liver tissue hydroxyproline (Hyp) and endothelin -1 (ET-1) levels, superior mesenteric vein The portal vein pressure was measured and the changes of pathological morphology of liver were observed and compared with the model group. [Results] The portal vein pressure of the treated group was significantly decreased, the levels of ALT, AST, Tbil and Hyp and ET-1 in liver tissue were significantly decreased compared with the model group, and the pathology showed that the treatment group returned to normal. [Conclusion] ET-1 in liver tissue is significantly increased in cirrhotic rats. SA-B can significantly reduce the portal pressure and hepatic ET-1 levels in cirrhotic rats.